Drug Approval | October 21, 2021
U.S. FDA gives green light to Moderna and J&J booster doses
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
Second interchangeable biosimilar product approved by agency
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
U.S. FDA to decide whether to authorize a booster dose in the coming days
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Subscribe To Our Newsletter & Stay Updated
